Use of Vasopressin in Septic Shock.
The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock. The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin. The main research questions are: * Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock? * What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients? Participants will: * Be admitted to an ICU with a diagnosis of septic shock. * Receive vasopressin as an adjunct to norepinephrine for hemodynamic support. * Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system. * Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.
⁃ Eligible patients for this study must comply with the following requirements.
• ICU admission with a septic shock diagnosis.
• Age 18 years or above at ICU admission.
• Use of vasopressin as an adjunct of norepinephrine.
⁃ For the purposes of this study, septic shock is defined by full compliance with the following criteria.
• Sustained arterial hypotension or serum lactate above 2 mmol/L.
• Adequate but unsuccessful fluid resuscitation.
• Vasopressor usage to maintain a mean arterial pressure above 65 mmHg.
• Probable or proven infectious etiology.
⁃ Patients with some of the following conditions will be automatically excluded.
• Pregnancy.
• Ischemic cardiogenic shock.
• Acute intestinal ischemia.
• Readmission to the Intensive Care Unit.